Patients with a type of non-Hodgkin lymphoma, called follicular lymphoma and have not yet had previous systemic treatment, such as chemotherapy or immunotherapy will be invited to participate. This research study is being conducted in order to evaluate the combination of lowdose methotrexate and Iodine I 131 tositumomab (Bexxar) with regards to whether the combination will reduce the occurrence of the HAMA (Human Anti-Mouse Antibody) response. HAMA is an immune reaction against the tositumomab protein. Symptoms arising from HAMA can range from a mild form, like a rash, to a more extreme and possibly life-threatening level. HAMA can also decrease the effectiveness of the treatment, or create a future reaction if a patient is given another treatment containing mouse antibodies. In addition to evaluating the occurrence of HAMA, this research study will also look at the short and long-term effectiveness of this combination in the treatment of lymphoma, as well as its safety.

Start Date01 Jul 2011

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

[+1]

NCT00770224

/ CompletedPhase 2IIT

A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma

RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving a radiolabeled monoclonal antibody together with rituximab and combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects of giving iodine I 131 tositumomab together with rituximab and combination chemotherapy and to see how well it works in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.

Start Date01 Apr 2009

Sponsor / Collaborator

National Cancer Institute

NCT00484874

/ CompletedPhase 1/2IIT

A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab (Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what side effects these patients get when they take Bexxar® and if Bexxar® is effective in treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of radiation to cancer cells.

Start Date01 Jun 2007

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Iodine 131 tositumomab

100 Translational Medicine associated with Iodine 131 tositumomab

100 Patents (Medical) associated with Iodine 131 tositumomab

278

Literatures (Medical) associated with Iodine 131 tositumomab

01 Jul 2024·SEMINARS IN NUCLEAR MEDICINE

The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?

Review

Author: Wahl, Richard L ; Kahl, Brad

In Greek mythology, The Phoenix is an immortal bird that dies, but then achieves new life by rising from the ashes of its predecessor. Radioimmunotherapy (RIT) of B-cell Non-Hodgkin lymphoma (NHL) is a field which once began to fly high-with FDA approval of the anti-CD20 RITs Zevalin® and Bexxar® in 2002 and 2003 respectively, as safe and effective therapies of NHL. However, despite their therapeutic efficacy, Bexxar® was withdrawn from the market by the manufacturer in 2014 due to limited commercial demand and Zevalin® has had very limited to no availability of late. I-131 rituximab is used to a limited extent in Australia, India and other countries, as well. But has RIT of NHL been (perhaps prematurely) left for dead by many? Given the current great clinical and commercial interest in radiopharmaceutical therapies of cancer, notably PSMA and SSTR targeting agents in prostate and neuroendocrine cancers, can radioimmunotherapy of NHL-like the mythical Phoenix-now rise from its ashes in an even better form to fly higher, faster, farther and longer than before?

04 Apr 2024·The oncologist

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma

Review

Author: Gopal, Ajay K ; Durando, Michael ; Persky, Daniel ; Tuscano, Joseph

Abstract:

Purpose:

The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biopharma) and 131 I-tositumomab (131-IT, Bexxar, GlaxoSmithKline) both target CD20. The aim of this study was to review the clinical applications and supporting clinical trial data of anti-CD20 RIT for lymphoma.

Methods:

A review of published articles and abstracts on the clinical efficacy and safety of 90Y-IT and iodine I 131 tositumomab was performed.

Results:

The clinical efficacy and safety of anti-CD20 RIT have been demonstrated in numerous clinical trials and case series. Agents have produced significant responses in patients with follicular NHLs and in off-label applications. Importantly, RIT has demonstrated promising findings in high-risk lymphomas and heavily pretreated and refractory patient populations. Associated toxicity profiles are noted as tolerable, acceptable, and most often reversible.

Conclusions:

In the 2 decades since its approval, anti-CD20 RIT continues to demonstrate efficacy, particularly with a proportion of patients maintaining long-term remissions. The combination of prolonged efficacy, tolerability, and treatment convenience makes RIT a reasonable alternative to other systemic therapies. It is recommended that further research on RIT should focus on biomarkers of long-term response, pretargeting, and sequencing of RIT in the treatment course.

12 Sep 2023·Blood advances

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.

Article

Author: Spence, Janice M ; Li, Hongli ; Shadman, Mazyar ; Smith, Sonali M ; Friedberg, Jonathan W ; Leonard, John P ; Burack, W Richard ; Spier, Catherine M ; Leblanc, Michael L ; Adlowitz, Diana ; Kaminski, Mark S ; Rimsza, Lisa M

Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal TP53 mutations (median allele frequency 0.02) were found in 25% of diagnostic FL specimens and in 27% of a separate validation cohort. In the R-CHOP arm, pathogenic TP53 mutations were not associated with progression-free survival (PFS) (10-year PFS 43% vs 44%). In contrast, among patients with no detectable pathogenic TP53 mutation, RIT-CHOP was associated with a longer PFS than with R-CHOP (10-year PFS 67% vs 44%; hazard ratio = 0.49; P = .008). No relationship was detected between PFS and the extent of activation-induced cytidine deaminase (AICDA)-mediated heterogeneity. In summary, subclonal TP53 mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. The absence of a detectable subclonal mutation in TP53 defined a population that particularly benefited from RIT.

News (Medical) associated with Iodine 131 tositumomab

15 Aug 2023

·www.biopharmadive.com

Radiopharmaceuticals for cancer: Making radiation precise

Editors note: BioPharma Dive, as part of Emerging Biotech Weekly, is taking a closer look at competitive areas of startup activity. We aim to give an overview of the companies developing a new technology and what their goals are.When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drugs maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age.The medicine, Pluvicto, is known as a radiopharmaceutical. Unlike the small molecule or biologic medicines drugmakers use to flip cellular switches on or off, radiopharmaceuticals are designed to precisely deliver radioactive material into the body. The result is a targeted punch of radiation that can knock out tumors in a way other drugs cant.However, since Pluvictos approval, Novartis has struggled to meet demand, highlighting one of the many issues that has slowed development of radiopharmaceuticals. Theyre difficult to produce, distribute and administer. The earliest examples never lived up to commercial expectations, hamstrung by manufacturing problems, competition, high costs and safety concerns. GSK stopped making one, known as Bexxar, in 2014. Another, named Zevalin and originally developed by Idec Pharmaceuticals, never became a big seller.A group of companies, from biotechnology startups to pharmaceutical giants, think theyve solved these problems. Borrowing from progress in another cancer drug field, theyre leaning on technical advancements that have enabled researchers to design medicines capable of safely delivering a radioisotope to just the right spot.Novartis is the most invested, having spent $6 billion on acquisitions of Endocyte and Advanced Accelerator Applications. Right alongside Novartis is Bayer, which has also brought a radiopharmaceutical to market and is testing others.Behind them are a handful of publicly traded companies and at least a dozen biotech startups, making radiopharmaceuticals a hotly competitive area of drug research. Heres where things stand:What are radiopharmaceuticals, and how do they work?Born shortly after the discovery of the X-ray, radiation therapy has more than a century of history in cancer treatment. Its a way of using high-energy particles or waves to damage the DNA of cancer cells, preventing division and growth.Along with surgery, radiation therapy is a mainstay of cancer care, used to treat or prevent the recurrence of tumors in more than half of people with the disease, according to the American Cancer Society.But radiation therapy is a blunt force. Rays beamed from outside the body can damage healthy tissue, while a more targeted, inside-the-body approach is costly and complex.By comparison, radiopharmaceuticals can deliver the destructive power of radiation directly into tumors. They are akin to microscopic smart bombs radioactive material guided by a molecular courier to cells with specific protein flags.With Novartis drug Pluvicto, a radioisotope known as lutetium is chemically fused to a small molecule that binds to PSMA, a protein overexpressed in most prostate cancers. Novartis other radiopharmaceutical, Lutathera, delivers radioactive lutetium to SSTR, a target found on certain neuroendocrine tumors.The drugs are complex, made of hand-picked parts. Different radioactive materials may weigh more or less, last longer or pack a bigger punch. Some radiopharmaceuticals may require a chelator, a molecule that keeps the radioactive material intact as its carried through the body.Drugmakers also have to design chemical linkers that hold their therapies together, but dont stick around too long after reaching their target. A molecular guide that seeks out malignant cells is another necessary component.Once designed, radiopharmaceuticals are tricky to produce at scale. Supplies of radioactive materials are limited, and their transport is controlled. The drugs must be made and delivered quickly, before the radioactive components decay too much.Why are radiopharmaceuticals a hot area of investment?Interest in radiopharmaceuticals mirrors the ascent of another class of targeted cancer medicines, known as antibody-drug conjugates, or ADCs.Like radiopharmaceuticals, ADCs deliver a toxic substance, usually a chemical, directly to a tumor. After years of slow progress, theyve undergone a renaissance catalyzed by technical advances, regulatory approvals and interest from large drugmakers. Venture investors are in turn backing new startups.Radiopharmaceuticals are now in the spotlight, too. Despite the poor sales of the fields first medicines, newer drugs are performing better. Studies supporting some, like Pluvicto, have shown radiopharmaceutical drugs can extend survival and, in some cases, outperform other types of treatments.Radiopharmaceutical drugs are now being recognized as an effective, safe, and economically and logistically viable treatment modality, wrote physicians from Johns Hopkins University School of Medicine and Memorial Sloan Kettering Cancer Center, in a 2020 article in Nature Reviews Drug Discovery.As is often the case, large pharma investment is sparking a chain reaction of activity. Novartis acquisitions of Advanced Accelerator and Endocyte yielded Lutathera and Pluvicto, which, despite production challenges, are seeing strong demand. Bayer reached close to $500 million in peak yearly sales with its radiopharmaceutical Xofigo; its now working on newer medicines and, in 2021, acquired two startups.Diagnostics company Lantheus Holdings bought the maker of Azedra, another radiopharmaceutical recently approved by the FDA for rare neuroendocrine tumors.Those deals, along with radiochemistry advances and a greater ability to innovate in complex therapeutic modalities, have spurred a wave of investments in new radiopharmaceutical companies, wrote Faisal Khurshid, an analyst with Leerink Partners, in a report last year.Some, like the publicly traded biotech Fusion Pharmaceuticals and startup RayzeBio, are going after the same targets as Pluvicto and Lutathera, but with different radioactive components or guiding molecules.Others are pursuing different cancer-associated proteins. The startup Abdera Therapeutics has a program in development aimed at DLL3, a long-studied target in a tough-to-treat form of lung cancer. Belgian biotech Precirix is evaluating a radiopharmaceutical for tumors driven to growth by HER2, a well-known cancer gene.Radiopharmaceutical drug startups are drawing interest from a range of biotech VC firmsCompanyTop investorsFunds raised (in millions)Rayze BioVenBio, Versant Ventures, Samsara Biocapital, Sofinnova Investments$418ITMTemasek, Blackrock, Nextech255Aktis OncologyMPM Capital, EcoR1 Capital, Vida Ventures, Merck & Co.$161Abdera TherapeuticsVenBio, Versant Ventures, Amplitude Ventures$142PrecirixForbion, Jeito Capital, INKEF Capital117Convergent TherapeuticsOrbiMed, RA Capital Management$90Alpha-9 TheranosticsLongitude Capital, BVF Partners, Nextech$86Mariana OncologyAtlas Venture, RA Capital, Access Biotechnology$75Ariceum TherapeuticsHealthcap, EQT Life Sciences48Ratio TherapeuticsDuquesne Capital, Schusterman Family Investments$40Radionetics5Am Ventures, Frazier Health Care Partners$30ArtbioF-Prime Capital, Omega Funds$23SOURCE: CompaniesWhich companies are working on it, and who is backing them?More than a dozen radiopharmaceutical startups have launched in recent years. Many have pulled in sizable funding rounds, sometimes with overlapping investor groups.In April, Abdera debuted with $142 million in funding and backers led by venBio and Versant Ventures. Those two investors also launched RayzeBio, which has raised $418 million since its start, making it one of the fields most well-funded companies.Convergent Therapeutics launched in May with $90 million from RA Capital Management and OrbiMed. RA Capital also helped incubate Mariana Oncology alongside Atlas Venture and Access Biotechnology.Aktis Oncology has secured $161 million in funding from Novartis, Merck & Co. and Bristol Myers Squibb, among others, since arriving in 2021.Precirix is backed by Forbion and Jeito Capital and has raised 117 million euros since 2018. Germany-based Isotope Technologies Munich, or ITM, in June secured 255 million euros in a large funding round for a European biotech.Artbio debuted in June with seed funding from Omega Funds and F-Prime Capital. Its run by Emanuele Ostuni, the former head of Novartis Oncologys cell and gene therapy operations in Europe, and was founded by the inventors of Xofigo.Other firms in the mix include Frances Atonco Pharma, Australias GlyTherix, China-based Ablaze Pharmaceuticals, University of Connecticut spinout Nami Therapeutics and Boston-based Ratio Therapeutics.These young companies join a handful of publicly traded biotechs, like Fusion, Plus Therapeutics and Point Biopharma, as well as initiatives started by diagnostics firms or suppliers of nuclear material.How far along are these new companies?Unlike other hotspots of startup activity, radiopharmaceutical developers are, in many cases, already deep into clinical development.Several companies are testing drugs that, like Lutathera, target tumors expressing the protein SSTR. RayzeBio began a Phase 3 trial in May, while ITM is further along in its late-stage program. Molecular Targeting Technologies, Arecium Therapeutics and Orano Med also have SSTR-targeting medicines in human trials.A group of developers are following in Pluvictos footsteps with drugs aimed at cells expressing PSMA. Curium Pharma has a Phase 3 study underway in prostate cancer. Point and partner Lantheus are expecting late-stage results later this year. Medicines from Fusion, Convergent and Advancell are in earlier stages.ArtBios lead program is also for prostate cancer and has entered human trials. It uses a radioactive isotope called Pb212 that the startup claims has an ideal clinical profile. Advancell and Orano Med use Pb212 as well.Other companies are earlier in their journeys. Aktis, for example, hasnt disclosed a lead program. But it has revealed the radioactive material, Actinium-225, it intends to deliver with drugs. Abdera plans to ask regulators next year to begin its first trial. '

Drug ApprovalAcquisitionPhase 3Radiation Therapy

21 Apr 2023

·medcitynews.com

Cancer Biotech Abdera Reveals $142M for Better Antibody-Based Radiation Drugs

Less than three years ago, a group of Canadian scientists got together to brainstorm a better radiopharmaceutical. Radiation has a long history in cancer care, used in imaging to detect the disease as well as in therapeutics that treat it. Radiopharmaceuticals, therapies that deliver a radioactive substance that kills cancer cells, have seen a research resurgence in recent years as big pharmaceutical companies and biotech startups aim to make these therapies more effective against tumors and less toxic to healthy tissue. The scientists, based in Vancouver, British Columbia, settled upon an idea that they thought could set them apart from the growing radiopharmaceuticals field. They formed a company, secured some initial financing, and then validated their approach in preclinical research. On Thursday, their startup, Abdera Therapeutics, revealed its science along with $142 million in financing behind it. Abdera, which now splits its operations between Vancouver and Menlo Park, California, came about as a thought exercise, said Adam Judge, one of the co-founders and the startup’s senior vice president of research. Judge’s experience includes senior roles at Genevant Sciences and Tekmira Pharmaceuticals, where his research included building delivery systems for hard-to-deliver drugs. Mike Abrams, another co-founder and a senior advisor to Abdera, has extensive experience in radiopharmaceutical imaging agents. The third co-founder, Lana Janes, was a venture partner at adMare BioInnovations, where Abdera incubated. She is now the startup’s senior vice president, operations and innovation. The scientists tossed about various ideas for improving radiopharmaceuticals. Wherever the radio-particle goes in the body is where you’re going to see toxicity, Judge said. Ideally, a radiopharmaceutical will deliver as much of the isotope to the tumor as possible, while also clearing out of other tissues to avoid causing toxic effects. Some research efforts are employing small molecules or peptides to target the delivery of a radiopharmaceutical. The problem with both approaches is that the therapy is excreted through the kidneys, which leads to toxic effects there, Judge said. That toxicity problem led the founders to turn to antibodies. Antibodies avoid the kidneys, and the idea of using an antibody for targeted delivery of a radioisotope has been done successfully. The non-Hodgkin lymphoma radiopharmaceuticals Zevalin, approved in 2002, and Bexxar, approved in 2003, were both made with antibodies from mice. But even though these early antibody-based radiopharmaceuticals avoided the kidneys, they still caused other side effects. Because of their long half-lives, they stayed around for a long time in circulation, causing systemic toxicities, Judge said. Neither Zevalin nor Bexxar was commercially successful and both were eventually discontinued by their manufacturers. The Abdera scientists still liked the idea of working with antibodies. But rather than using a mouse antibody or repurposing an existing one, Abdera’s founders decided to start from scratch. Abdera’s engineered antibodies behave like a conventional antibody, offering similar targeting capabilities, Judge said. But at half the size and half the molecular weight of a typical antibody, Abdera’s antibodies are better able to penetrate into solid tumors. Furthermore, they don’t stay around in circulation long enough to cause systemic side effects. “Wherever the antibody goes, the isotope goes,” Judge said. “The antibody drives the clearance.” The accelerated clearance of the antibody is driven through the liver. This approach is preferred to the kidney because the liver is a large organ that can handle a large radioactive dose and clear the isotope through the gut, Judge said. Also, the liver is more radioresistant than the kidney and it has the capacity to regenerate if needed. In preclinical testing, Abdera saw good biodistribution into the tumor, as well as adequate and rapid clearance of the therapy from tissues, Judge said. The biodistribution data serve as a positive sign of finding a therapeutic window, the dose range that balances safety and efficacy. The results also show high uptake of therapy by a variety of solid tumors. Abdera launched in early 2021 backed by 8 million Canadian dollars in seed financing from adMare BioInnovations and AbCellera Biologics, a Vancouver-based antibody developer. In mid-2021, the startup was able to raise its Series A financing, which was led by Versant Ventures and Amplitude Ventures. Other investors in the round include Northview Ventures as well adMare BioInnovations and AbCellera. Judge said Abdera didn’t announce the $32.5 million Series A round at the time because the startup did not yet have a story to tell. The cash came before the company had shown its technology can work in animal testing. Those data came soon enough. Abdera went “from a thought exercise to in vivo preclinical proof of concept in 10 months,” Judge said. On the heels of achieving the key preclinical data, the company was able to raise more money. The $110M Series B round is new cash announced Thursday. The latest financing was led by venBio Partners with participation from the earlier investors as well as new ones, including Viking Global Investors, Qiming Venture Partners USA and RTW Investments. The preclinical data that caught investor interest showed Abdera was able to hit five cancer targets. The startup is disclosing just one of them: Delta-like ligand 3, or DLL3. This protein is expressed in a variety of solid tumor types while also being rarely found on healthy cells. Abdera’s lead program, ABD-147, is being developed for treating small cell lung cancer. Radiopharmaceuticals are seeing stronger research interest as two new Novartis therapies gain traction in the market, said Abdera President & CEO Lori Lyons-Williams, a former executive at neuroscience drug startup Neumora. In 2018, the FDA approved Novartis’s Lutathera as a treatment for certain gut cancers. Last year, the FDA approved Pluvicto, a bladder cancer radiopharmaceutical that Novartis added via its $2.1 billion acquisition of Endocyte. “The medical community has been more willing to adopt them,” she said. “I think that’s a reason why there’s been a renaissance in radiopharmaceuticals.” Novartis is looking to expand its radiopharmaceutical scope beyond Lutathera and Pluvicto. Last month, the pharma giant paid $50 million up front to start a partnership focused on developing new radiopharmaceuticals based on the peptide technology of Bicycle Therapeutics. Among the advantages touted by the Cambridge, U.K.-based biotech is kidney excretion—it avoids liver toxicity. Bayer entered the radiopharmaceutical field with 2021 acquisitions of Noria Therapeutics and PSMA Therapeutics. Other radiopharmaceutical companies in the space include Aktis Oncology, a startup with financial backing from Novartis and Bristol Myers Squibb; Mariana Oncology, a startup that emerged from stealth in 2021 as Curie Therapeutics; and RayzeBio, a company that like Abdera, counts Versant Ventures as an investor. Venture capital firms usually don’t bet against their own portfolio companies. In Abdera’s funding announcement, Joel Drewry, principal at Versant, said his firm believes “Abdera’s approach represents a new wave of innovation in this space to address important cancer targets that may be intractable to other approaches.” Lyons-Williams joined Abdera last May when the company had nine employees. Current headcount is 30. Lyons-Williams expects to add 15 more by the end of this year as Abdera works toward an investigational new drug application filing for ABD-147 in 2024. The targets for Abdera’s four other programs remain undisclosed. Lyons-Williams said some are targets that have clinical validation but have yet to lead to successful therapies with other drug modalities due to toxicity. In other cases, the target is one that few drug hunters are pursuing. She added that once Abdera is able to show clinical validation of its technology, the company may be able to go after novel cancer targets as well. Photo by Abdera Therapeutics

Drug ApprovalAcquisition

100 Deals associated with Iodine 131 tositumomab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Iodine 131 tositumomab	V10XA53	DB00081

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Hodgkin Lymphoma	US	GlaxoSmithKline LLC	27 Jun 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Follicular Lymphoma	Phase 3	US	GSK Plc	01 Oct 2004
Follicular Lymphoma	Phase 3	FR	GSK Plc	01 Oct 2004
Follicular Lymphoma	Phase 3	GB	GSK Plc	01 Oct 2004
Refractory Hodgkin Lymphoma	Phase 2	US	GSK Plc	01 Jun 2007
Recurrent Non-Hodgkin Lymphoma	Phase 2	US	GSK Plc	01 Jan 2007
Relapse multiple myeloma	Phase 2	US	GSK Plc	01 Aug 2005
Diffuse large B-cell lymphoma recurrent	Phase 2	US	GSK Plc	01 Sep 2004
Indolent Non-Hodgkin Lymphoma	Phase 2	CA	GSK Plc	01 Apr 2004
Mantle-Cell Lymphoma	Phase 2	-	GSK Plc	28 Jun 2001
Diffuse Large B-Cell Lymphoma	Phase 2	US	Corixa Corp.	01 Jan 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00022945 (Pubmed \| Clin Lymphoma Myeloma Leuk) Manual	Phase 2	Mantle-Cell Lymphoma First line	25	Cyclophosphamide+Doxorubicin+Vincristine+Prednisone+Iodine-131 Tositumomab	eaypssorkc(gusoqepmfm) = eqltfyexek cuniyhqsce (ujggrcbncf ) View more	Positive	01 Nov 2020
NCT00484874 (CTgov)	Phase 1/2	Refractory Hodgkin Lymphoma	12	I-131 Tositumomab therapeutic regimen	hkcqarhhzf(ykarocbrsy) = btnqfvdcde eeulehuyjp (picjzgjhgt, wwironmmqb - azwyayvonu) View more	-	01 Aug 2018
NCT00490490 (CTgov)	Phase 2	Recurrent Non-Hodgkin Lymphoma	8	External beam radiotherapy (XRT)+Potassium Iodide (KI)+Bexxar (tositumomab)	mxyaixbjuu(sfnygcqhjk) = jmlzrvcrrl mdxvwvlvro (mzbhxmufch, zsafwypzfh - pplnfjsqte) View more	-	29 Mar 2017
NCT00490009 (CTgov)	Phase 2	Diffuse large B-cell lymphoma recurrent	9	Bexxar (Bexxar)	zdrrlfilrt(kanghqdqhg) = qyufbkgajq tngqtyvuhz (qqcclbbkow, pqjjfwmvhk - kquiqqwufx) View more	-	28 Feb 2017
NCT00490009 (CTgov)	Phase 2	Diffuse large B-cell lymphoma recurrent	9	SSKI+Tylenol+Bexxar+Benadryl (Bexxar + Tylenol + Benadryl + SSKI)	bktudrbqvm(xbfsuuasvj) = swjhxxhndb vrxnhownkq (ptfnhrtsdg, itpzgidpol - unfglhqwlg) View more	-	28 Feb 2017
NCT01389076 (CTgov)	Phase 2	Follicular Lymphoma	22	Bexxar+Methotrexate	eokeftnfru(hudwahevzm) = qsjppahdwx euwcpcswzy (hzxadibaiv, nnegzgjmlp - xedapzalej) View more	-	12 Jul 2016
NCT01868035 (Pubmed \| Clin Lymphoma Myeloma Leuk) Manual	Phase 2	Diffuse Large B-Cell Lymphoma First line	15	CHOP+tositumomab+iodine-131 tositumomab	gepwrbjfmf(zgzxjhogpx) = hematologic adverse events were decreased absolute neutrophil count (47%), white blood cell count (40%), platelet count (27%), and hemoglobin (20%). tiaxlpoerw (zmwsnjwkdm )	Positive	01 Apr 2016
NCT00135200 (CTgov)	Phase 2	Relapse multiple myeloma \| Multiple Myeloma	16	Iodine I 131 Tositumomab	bfjcycfsyp(rhnwwsmivn) = awqgdytsku gtrymswrgi (lkhxpfflpa, srgwgsmlsj - cjwktzuybb) View more	-	20 Nov 2014
NCT00938041 (CTgov)	Phase 2	Non-Hodgkin Lymphoma	32	Tositumomab	syljpkvmml(fqsdrlwjdy) = wwnhlzytpw ehhmgsiutr (kgtlnchnlq, hwwlnanzwm - iqlsomsigb) View more	-	08 Apr 2014
NCT00992992 (CTgov)	Phase 2	Mantle-Cell Lymphoma	25	CHOP+Iodine I-131 Tositumomab	wnpyypgdtl(aisdvtkyrc) = figuccupde azmnofrbda (qgfhiixrzv, fykxycjqjn - abeqhidoay) View more	-	08 Apr 2014
NCT01868035 (CTgov)	Phase 2	Diffuse Large B-Cell Lymphoma	15	Anti-B1 antibody of Tositumomab (TST)+Iodine-131	kddzpdkghy(bnnsttjezh) = alkblxtjjx tagqqeblvb (inigmkxcer, phdugmydne - xslufnwugj) View more	-	12 Sep 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis